Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.43.EBIT: As of FY2026 Q1, the actual value is USD -2.205 M.Shuttle Pharmaceuticals Holdings, Inc. operates as a single segment focused on developing novel drug therapies and utilizing its Molecule.ai platform.<h4>Segment Revenue</h4>Shuttle Pharmaceuticals Holdings, Inc. reported no revenues for the three months ended March 31, 2026, and March 31, 2025.<h4>Operational Metrics (Three Months Ended March 31, 2026 vs. 2025)</h4><ul><li>Research and Development (R&amp;D) Expense: R&amp;D expense decreased by $1,306,688, or 83%, from $1,573,928 in 2025 to $267,240 in 2026. This reduction was primarily due to a $0.9 million decrease in subcontractor expenses and a $0.2 million decrease in R&amp;D compensation-related expenses, which were $0.2 million in 2026 compared to $0.6 million in 2025, largely due to lower employee headcount and the CSO’s retirement.</li><li>General and Administrative Expenses: These expenses increased by $563,670, or 94%, from $596,886 in 2025 to $1,160,556 in 2026, mainly attributed to $0.1 million in advertising costs for investor relations and $0.6 million in amortization expense for developed technology.</li><li>Legal and Professional Expenses: These expenses saw a slight increase of $8,599, or 1%, from $780,427 in 2025 to $789,026 in 2026.</li><li>Total Operating Expenses: Total operating expenses decreased by $734,419, or -25%, from $2,951,241 in 2025 to $2,216,822 in 2026.</li><li>Net Loss from Operations: The net loss from operations was -$2,216,822 in 2026, an improvement from -$2,951,241 in 2025.</li><li>Net Loss: The net loss decreased by $900,536, or -29%, from -$3,053,007 in 2025 to -$2,152,471 in 2026.</li><li>Other Income (Expense): Other income increased by $166,117, or -163%, changing from an expense of -$101,766 in 2025 to income of $64,351 in 2026. This was driven by a $0.1 million increase in the change in fair value of derivative liabilities, partially offset by a $0.09 million decrease in the change in fair value of convertible notes.</li><li>Change in Fair Value of Derivative Liabilities: This resulted in a gain of $76,264 in 2026, up from a gain of $2,643 in 2025, an increase of 2,786%.</li><li>Change in Fair Value of Convertible Notes: This was $0 in 2026, compared to a loss of -$92,479 in 2025, representing a -100% change.</li></ul><h4>Cash Flow (Three Months Ended March 31, 2026 vs. 2025)</h4><ul><li>Net Cash Used in Operating Activities: Net cash used was -$2,417,309 in 2026, a 4% decrease from -$2,526,924 in 2025.</li><li>Net Cash Used in Investing Activities: Net cash used was -$36,000 in 2026, primarily for capitalized software development costs, compared to $0 in 2025.</li><li>Net Cash Provided by Financing Activities: Net cash provided was $3,209,250 in 2026, a -37% decrease from $5,119,387 in 2025. The 2026 financing activities included $3.5 million from the sale of common stock and pre-funded warrants, net of $0.3 million in placement agent costs.</li><li>Cash and Cash Equivalents on Hand: Total cash and cash equivalents were $1,089,946 as of March 31, 2026, a -76% decrease from $4,512,607 as of March 31, 2025.</li></ul><h4>Unique Metrics</h4><ul><li>Working Capital Deficit: As of March 31, 2026, the working capital deficit was -$5.8 million, an improvement from -$7.5 million as of December 31, 2025. Current assets were $2.5 million and current liabilities were $8.3 million as of March 31, 2026.</li><li>Stockholders’ Equity: As of March 31, 2026, total stockholders’ equity was $3,346,243, up from $2,254,446 as of December 31, 2025.</li><li>Molecule.ai Asset Acquisition: On November 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. acquired substantially all assets of Molecule.ai, an AI-driven platform, for a total purchase consideration of $10,117,304. This included a $3,000,000 cash payment, 320,496 shares of common stock valued at $564,073, and contingent consideration of up to $2,000,000 based on technology development milestones. The developed technology asset had a carrying value of $9,244,910 as of March 31, 2026, after amortization expense of -$632,332 and capitalized software additions of $36,000 during the quarter.</li></ul><h4>Future Outlook and Strategy</h4>Shuttle Pharmaceuticals Holdings, Inc. does not expect to generate positive cash flows from operating activities in the near future and faces substantial doubt about its ability to continue as a going concern within one year. The company’s continued operations depend on successfully raising additional equity or debt financing to fund operations, milestone and contingent payments, and to commercialize and market the Molecule.ai platform. The company intends to use up to $1.5 million of net proceeds from its March 2026 offering for future marketing efforts and the remainder for working capital and general corporate purposes, but these funds are not expected to be sufficient for operations through the next twelve months.

Shuttle Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0